作者: Yashiro, Mitsuru ; Negi, Shigeo ; Kawakami, Kazuki ; Mima, Toru ; Yano, Takurou ; Kobayashi, Sou ; Tanaka, Yusuke ; Tatsuta, Koichi ; Shigematsu, Takashi ; Sonou, Tomohiro ; Yamamoto, Shuto ; Nakashima, Yuri ; Ohya, Masaki

Osteocytes play an important role in the regulation of serum phosphorus by producing fibroblast growth factor 23 (FGF23). FGF23 production is stimulated by 1α,25-dihydroxyvitamin D in osteocytes. However, it is unclear whether vitamin D induces FGF23 production in osteocytes directly. Therefore, we investigated vitamin D-induced FGF23 production in osteocyte-like cells derived from MC3T3-E1 osteocyte progenitor cells. We also investigated differences in the induction of FGF23 by 1α,25-dihydroxyvitamin D and various vitamin D analogs. MC3T3-E1 cells were differentiated into osteocyte-like cells (MCT3-E1-OLCs) by treatment with various agents including β-glycerophosphate and ascorbic acid. MCT3-E1-OLCs were stimulated with 1α,25-dihydroxyvitamin D₃ and subsequent FGF23 gene expression was 2631 ± 605 times higher compared with untreated cells. The expression of FGF23 in MCT3-E1-OLCs transfected with a knockdown sequence against vitamin D receptor (VDR) was significantly decreased compared with that in cells transfected with the control vector. Therefore, the induction of FGF23 in osteocytes by vitamin D may be primarily mediated via VDR. The potential of 25(OH)vitamin D₃, paricalcitol, and maxacalcitol to induce FGF23 production was almost the same as that of 1α,25-dihydroxyvitamin D₃. However, falecalcitriol and eldecalcitol demonstrated a reduced potential to induce FGF23 compared with 1α,25-dihydroxyvitamin D₃. Our results demonstrate that FGF23 induction is different among the analogs of 1α,25-dihydroxyvitamin D₃. Therefore, an appropriate vitamin D analog should be chosen for each patient with mineral and bone disorder, considering its effect on FGF23 production.

2018-03-01·The Journal of Steroid Biochemistry and Molecular Biology2区 · 生物学

Recent developments for introducing a hexafluoroisopropanol unit into the Vitamin D side chain

2区 · 生物学

Review

作者: Kittaka, Atsushi ; Sugiyama, Toru ; Uesugi, Motonari ; Kawagoe, Fumihiro

Among numerous studies on synthetic approaches to and the biological activities of vitamin D analogues, we herein focused on falecalcitriol, an analogue of calcitriol (1α,25-dihydroxyvitamin D₃), in which a 26,26,26,27,27,27-hexafluoroisopropanol unit has been introduced into the side chain. Falecalcitriol was designed to escape from the metabolism of CYP24A1 and has been used as a drug to treat secondary hyperparathyroidism since 2001. Its metabolite, the 23-hydroxy form, retains biological activity and resistants to further metabolism. Recent developments in synthetic methodologies for introducing the hexafluoroisopropanol unit into the vitamin D CD-ring side chain were described herein.

2017-03-01·Clinical and Experimental Nephrology3区 · 医学

Research on kidney and mineral metabolism in Japan: past, present, and future

3区 · 医学

Review

作者: Ogata, Hiroaki ; Akizawa, Tadao ; Mizobuchi, Masahide ; Kinugasa, Eriko ; Koiwa, Fumihiko

Since the identification of the kidney was the main site for the synthesis of calcitriol (1α, 25-dihydroxycholecalciferol), research on chronic kidney disease (CKD)-associated mineral metabolism disorders and their management has made rapid progress. Various active analogues of calcitriol have clinically become available for treating secondary hyperparathyroidism (SHPT), which is a representative mineral metabolism abnormality in CKD patients. A calcimimetic compound cinacalcet hydrochloride has also been developed for the medical management of SHPT through a different mechanism involving the calcium-sensing receptor. The concept of CKD-mineral and bone disorder (CKD-MBD) was proposed in 2006 to provide a comprehensive understanding of a disorder related to mineral metabolism abnormalities of CKD, based on the fact that these abnormalities are closely associated with cardiovascular disease as well as bone disorders (renal osteodystrophy). There has been a recent surge in the development of phosphate binders for CKD-MBD, focused on an effort to improve mortality. In Japan, high-quality basic and clinical research on CKD-MBD has led to the development of novel therapeutic drugs, such as maxacalcitol, falecalcitriol, and bixalomer. New practice guidelines have been published and are widely adapted in clinical practice.

100 项与氟骨三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01662	氟骨三醇	A11CC	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
甲状旁腺功能亢进症	日本	Sumitomo Pharma Co., Ltd.	2001-04-04
继发性甲状旁腺功能亢进症	日本	Kissei Pharmaceutical Co., Ltd.	2001-04-01
甲状旁腺功能减退症	日本	Kissei Pharmaceutical Co., Ltd.	2001-04-01
骨软化	日本	Kissei Pharmaceutical Co., Ltd.	2001-04-01
佝偻病	日本	Kissei Pharmaceutical Co., Ltd.	2001-04-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
绝经期后骨质疏松	临床1期	美国	Windtree Therapeutics, Inc.	1997-12-08
老化	临床1期	美国	Penederm, Inc.	1997-06-05
绝经期后骨质疏松	临床前	美国	Windtree Therapeutics, Inc.	1997-12-08
寻常痤疮	临床前	美国	Mylan Bertek Pharmaceuticals, Inc.	-
肾脏疾病	临床前	日本	Taisho Pharmaceutical Co., Ltd.	-
光线性皮肤障害	临床前	美国	Mylan Bertek Pharmaceuticals, Inc.	-
银屑病	临床前	美国	Mylan Bertek Pharmaceuticals, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAIC2011	N/A	阿尔茨海默症 Aβ protein	32	Bapineuzumab 0.15 mg/kg	鹽醖製襯艱鏇遞鏇壓窪(襯鬱製獵淵構選鏇鑰壓) = 繭觸醖齋構鬱鬱繭淵鹽鏇壓夢鏇鬱範製壓廠鹹 (顧築窪夢選構鑰廠醖夢 ) 更多	-	2011-07-01
				Bapineuzumab 0.5 mg/kg	鹽醖製襯艱鏇遞鏇壓窪(襯鬱製獵淵構選鏇鑰壓) = 憲築壓窪淵鑰窪鑰糧獵鏇壓夢鏇鬱範製壓廠鹹 (顧築窪夢選構鑰廠醖夢 ) 更多